Skip to main content
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
Seres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 10, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced the appointment of Willard Dere, M.D., a seasoned industry executive, to its Board of Directors. Dr. Dere brings to Seres more than two decades of scientific, clinical, and strategic biopharmaceutical experience. He is currently Professor of Internal Medicine, Executive Director of Personalized Health, and Co-director of the Cen... 
Seres Therapeutics Initiates SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection
- Based on recent FDA interactions, the new SER-109 Clinical Study is to be designated a Phase 3 Trial - - SER-109 Phase 3 Trial is the first pivotal trial in the emerging field of microbiome-based oral therapeutics - - Phase 3 Trial initiation triggers a $20 million milestone payment from Nestlé Health Science - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 12, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced the... 
Seres Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will participate in a webcast discussion at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 13 at 4 p.m. PT. Live audio webcast will be available under the Investors and Media section of Seres’ website. A replay of the presentation will become available approximately... 
There are currently no upcoming events scheduled.
Stock Quote
 + 1.14 (0.00%)
07/20/17 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

Data provided by Nasdaq. Minimum 15 minutes delayed.